Edition:
United Kingdom

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

9.39USD
3:40pm GMT
Change (% chg)

$0.14 (+1.51%)
Prev Close
$9.25
Open
$9.29
Day's High
$9.39
Day's Low
$9.09
Volume
72,494
Avg. Vol
53,183
52-wk High
$14.63
52-wk Low
$7.54

Latest Key Developments (Source: Significant Developments)

Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION.KARYOPHARM THERAPEUTICS - ON DEC 1, CO ENTERED INTO AMENDMENT NO. 2 TO CONTROLLED EQUITY OFFERING SALES AGREEMENT, DATED DECEMBER 7, 2015 - SEC FILING.  Full Article

Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing‍​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Karyopharm Therapeutics Inc :Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing‍​.  Full Article

Karyopharm Q3 loss per share $0.65
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm reports third quarter 2017 financial results and highlights recent progress.Q3 loss per share $0.65.Q3 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.Karyopharm Therapeutics Inc - ‍expect to report top-line results of phase 2b storm study by april 2018​.  Full Article

Wellington Management Group Llp reports 11.83 pct passive stake in Karyopharm
Tuesday, 11 Oct 2016 

:Wellington Management Group Llp reports passive stake of 11.83 percent in Karyopharm Therapeutics Inc as of Sept 30 - SEC Filing.  Full Article

Karyopharm Therapeutics provides update on Phase 2b STORM study
Tuesday, 30 Aug 2016 

Karyopharm Therapeutics Inc : Intends to expand its Phase 2b storm study evaluating activity of selinexor in multiple myeloma .Intends to expand its Phase 2b storm study to include approximately 120 additional patients with penta-refractory MM.  Full Article

Karyopharm reports Q2 loss per share $0.84
Thursday, 4 Aug 2016 

Karyopharm Therapeutics Inc : Q2 loss per share $0.84 .Q2 earnings per share view $-0.76 -- Thomson Reuters I/B/E/S.  Full Article

Karyopharm says initiates phase 1 clinical trial with KPT-9274
Wednesday, 22 Jun 2016 

Karyopharm : Says first-In-Human, multi-center, open-label, dose-escalation trial is expected to enroll up to 175 patients .Says initiates Phase 1 Clinical Trial With Kpt-9274.  Full Article

Karyopharm Q1 loss per share $0.75
Monday, 9 May 2016 

Karyopharm Therapeutics Inc : Expects existing cash and cash equivalents will fund research and development programs and operations into middle of 2018 . Expects to end 2016 with at least $120 million in cash, cash equivalents and investments . Karyopharm reports first quarter 2016 financial results and highlights recent progress . Q1 loss per share $0.75 .Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock

* KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION